



Cerezyme in Egypt

The EDA named-patient coordination pathway — indicative 2026

RARE DISEASE · GAUCHER TYPE 1

The clinical situation

Cerezyme (imiglucerase) is an FDA-approved recombinant glucocerebrosidase enzyme replacement therapy for Type 1 Gaucher disease, dosed 2.5–60 U/kg IV every two weeks. Manufactured by Sanofi. Weight-based dosing, cold-chain shipment to an infusion centre, and periodic haematologic and visceral-volume monitoring are required. Infusion reactions are managed with premedication and rate titration.

The pathway, 5 steps

- 1 Consultation & diagnostic confirmation.** Treating metabolic / haematology specialist confirms GBA enzyme deficiency and Gaucher phenotype; weight-based dose calculated.
- 2 Infusion centre confirmed.** An Egyptian tertiary centre (Cairo, Alexandria) commits to biweekly infusion slots and monitoring.
- 3 EDA named-patient application.** Clinical rationale, enzyme assay, dose calculation, and product details are filed with the Egyptian Drug Authority for import clearance.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; refrigerated shipment booked to infusion schedule.
- 5 Infusion & monitoring.** Biweekly IV infusions under specialist supervision; haematologic and visceral-volume monitoring per label.

Indicative economics

Reference US cash-pay range: USD 14,000–20,000 per infusion (weight-based) drug-only. Cold-chain logistics, EDA documentation, infusion-centre fees, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-infusion timing

7–14 days from a complete EDA application to first-infusion delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** EDA named-patient package with enzyme-assay confirmation. **Logistics.** Cold-chain, temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating specialist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Cerezyme × Egypt first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/cerezyme-egypt.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team